Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial

Scandinavian Journal of Infectious Diseases

Volumn 45, Issue 7, 2013, Pages 543-551

  Andersson, Lars Magnus ^a   Vesterbacka, Jan ^b   Blaxhult, Anders ^b   Flamholc, Leo ^c   Nilsson, Staffan ^d   Ormaasen, Vidar ^e   Sönnerborg, Anders ^b   Gisslén, Magnus ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Combination antiretroviral therapy; HIV 1; Randomized controlled trial; Treatment na ve patients

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NORWAY; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SWEDEN; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NORWAY; PROSPECTIVE STUDIES; RNA, VIRAL; SWEDEN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84879084363     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.756985     Document Type: Article

References (19)

1. Department of Health and Human Services. P anel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US DHHS; 2012. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadoles centgl.pdf (accessed 2012).
2. Hicks C, King MS, Gulick RM, White AC Jr, Eron JJ Jr, Kessler HA, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 2004; 18: 775-9.
3. Squires K, Lazzarin A, Gatell JM, Powderly WG, P okrovskiy V, Delfraissy JF, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fi xed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defi c Syndr 2004; 36: 1011-9.
4. Sandstrom E, U hnoo I, A hlqvist-Rastad J, B ratt G, Berglund T, Gisslen M, et al. Antiretroviral treatment of human immunodefi ciency virus infection: Swedish recommendations . Scand J Infect Dis 2003; 35: 155-67.
5. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva, Switzerland: WHO; 2006.
6. Chesney MA, I ckovics JR, C hambers DB, G ifford A L, Neidig J, Zwickl B, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12: 255-66.
7. Eden A, A ndersson LM, A ndersson O, F lamholc L, Josephson F, Nilsson S, et al. Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naive HIV-1-infected patients. AIDS Res Hum Retroviruses 2010; 26: 533-40.
8. Sierra-Madero J, V illasis-Keever A, M endez P, M osqueda-Gomez JL, Torres-Escobar I, Gutierrez-Escolano F, et al. Prospective, randomized, open label trial of efavirenz vs lopinavir/ritonavir in HIV treatment-naive subjects with CD4 200 cell/mm3 in Mexico. J Acquir Immune Defi c Syndr 2010; 53: 582-8.
9. Orkin C, DeJesus E, Khanlou H, Stoehr A, Supparatpinyo K, Van de Casteele T, et al. ARTEMIS: 192-week effi cacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naï ve HIV-1-infected adults. J Int AIDS Soc 2010; 13: P3.
10. Molina J M, A ndrade-Villanueva J, E chevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week effi cacy and safety results of the CASTLE study. J Acquir Immune Defi c Syndr 2010; 53: 323-32.
11. Daar ES, T ierney C, F ischl MA, S ax PE, M ollan K, Budhathoki C, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154: 445-56.
12. Nettles RE, K ieffer T L, K won P, M onie D, H an Y, Parsons T, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005; 293: 817-29.
13. Mills A M, N elson M, J ayaweera D, R uxrungtham K, Cassetti I, Girard PM, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23: 1679-88.
14. Sax PE, T ierney C, C ollier A C, D aar ES, M ollan K, Budhathoki C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: fi nal results. J Infect Dis 2011; 204: 1191-201.
15. Gallant J E, D eJesus E, A rribas J R, P ozniak AL, G azzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60.
16. Cooper V, Moyle G J, Fisher M, Reilly G, E wan J, Liu H C, et al. Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz. AIDS Care 2011; 23: 705-13.
17. Maljkovic I Wilbe K, S olver E, A laeus A, L eitner T. L imited transmission of drug-resistant HIV type 1 in 100 Swedish newly detected and drug-naive patients infected with subtypes A, B, C, D, G, U, and CRF01 AE. AIDS Res Hum Retroviruses 2003; 19: 989-97.
18. Karlsson A, B jorkman P, B ratt G, E kvall H, G isslen M, Sonnerborg A, et al. Low prevalence of transmitted drug resistance in patients newly diagnosed with HIV-1 infection in Sweden 2003-2010. PLoS One 2012; 7: e33484.
19. Frentz D, Boucher C A, van de Vijver D A. T emporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. AIDS Rev 2012; 14: 17-27.